Accurate Power Measurement Using Power Line Communication

It is of interest to know the power consumed when a particular hardware module or software application of a device-under-test (DUT) such as a smartphone is triggered and run. While the DUT can be controlled externally for timed triggering of modules or applications of interest, such triggering can contaminate power measurement. This disclosure describes techniques to synchronize power measurement with events within a device-under-test. A program within the DUT can temporarily increase or decrease slightly the power consumption of the DUT. A slight increase (decrease) in power consumption is interpreted by the power meter as a one (zero) bit. Prior to an event of interest, the DUT generates a specific bit pattern to herald the start of the event. At the end of the event, the DUT generates another bit pattern. Power consumption attributable to the event is included in the power-consumption waveform between the start and the stop bit-patterns

Connectionist Temporal Modeling for Weakly Supervised Action Labeling

We propose a weakly-supervised framework for action labeling in video, where only the order of occurring actions is required during training time. The key challenge is that the per-frame alignments between the input (video) and label (action) sequences are unknown during training. We address this by introducing the Extended Connectionist Temporal Classification (ECTC) framework to efficiently evaluate all possible alignments via dynamic programming and explicitly enforce their consistency with frame-to-frame visual similarities. This protects the model from distractions of visually inconsistent or degenerated alignments without the need of temporal supervision. We further extend our framework to the semi-supervised case when a few frames are sparsely annotated in a video. With less than 1% of labeled frames per video, our method is able to outperform existing semi-supervised approaches and achieve comparable performance to that of fully supervised approaches.Comment: To appear in ECCV 201

Light Flicker Detector

Light flickering can be detrimental to humans even if imperceptible. Headaches, migraine, and/or eye strain can result from exposure to flickering light. This disclosure describes techniques to detect and monitor light flicker. An ambient light sensor detects flickering in environmental lighting. Environmental light intensity is measured over a wide spectrum covering the human perceptive range. The peak flicker frequencies (and their magnitudes), flicker percentages, etc. are determined. If a substantial amount of flicker (greater than a threshold) is detected, an alert is provided. Furthermore, auto-generated instructions enable users to determine the light source that is the source of flickering

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions

AbstractBackgroundIn this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new lesions.MethodsFrom June 2010 to October 2012, 102 patients with lung adenocarcinoma, harboring favorable EGFR mutations and treated with EGFR-TKI were analyzed. Definite new lesions were detected during EGFR-TKI therapy, even though the primary target tumors were controlled.ResultsOf the 102 patients, 57 continued and 45 discontinued EGFR-TKI therapy. The median overall survival was 529 days for the discontinuation group and 791 days for the continuation group (p = 0.0197). Median survival time after the discontinuation of EGFR-TKI was 181 days and 115 days in the discontinuation and continuation groups, respectively (p = 0.1776), whereas median survival time after the appearance of indolent new lesions was 204 days and 262 days, respectively (p = 0.0237).ConclusionContinuous EGFR-TKI administration in favorable EGFR-mutative lung adenocarcinoma patients with controlled primary tumors did not hinder the survival benefit, despite the appearance of new lesions